Pharmacies are getting a bad name when price myopia is the real culprit
A recent New York Times article took aim at pharmacies, but the major problem going unresolved is price myopia.
A recent New York Times article took aim at pharmacies, but the major problem going unresolved is price myopia.
Hospitals competing on pharma’s turf by supplying their own generics signals a tectonic shift, and don’t expect it to go away anytime soon.
While many critics are quick to point to a pharma company’s profits, you don’t hear enough about the money being made by the drug tort industry.
Sander Flaum wants pharma to push back on pricing legislation.
Sander Flaum urges Americans to ignore politicians’ calls to head north of the border for their prescription medication.
Even if drug manufacturers lower prices, it won’t fix the U.S healthcare system.
President Trump’s blueprint to lower drug prices hasn’t made it out of the brainstorm phase.
Cutting prescription drug prices has become one of the most popular campaign promises of our time.
I’m not suggesting that colleges become vocational schools. But don’t you think they should also help young people prepare for the life they’re going to be living?
Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?